ABT · NYSE
Abbott Laboratories (ABT) Stock Price & Fundamentals
Abbott Laboratories (ABT) closed at $1,064.49 on Oct 9, 2026, down 0.98% from the previous close of $1,075.07.
Share price, past year
1Y +33.58%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $1,064.49 |
| Sep 30, 2026 | $1,080.65 |
| Aug 31, 2026 | $1,050.81 |
| Jul 31, 2026 | $1,039.05 |
| Jun 30, 2026 | $1,018.05 |
| May 29, 2026 | $1,010.12 |
| Apr 30, 2026 | $943.09 |
| Mar 31, 2026 | $921.44 |
| Feb 27, 2026 | $942.70 |
| Jan 30, 2026 | $952.88 |
| Dec 31, 2025 | $909.97 |
| Nov 28, 2025 | $863.89 |
| Oct 31, 2025 | $801.94 |
Key statistics
- Market cap
- —
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- $45.13B
- Net income (TTM)
- $6.28B
- Shares outstanding
- —
- Dividend yield
- 0.23%
- 52-week range
- $783.61 – $1,088.74
Financials
Abbott Laboratories reported revenue of $44.33B for fiscal 2025, up 5.67% from fiscal 2024.
Abbott Laboratories earned net income of $6.52B in fiscal 2025, a net margin of 14.7%.
Fiscal 2025 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $44.33B | +5.7% | $6.52B | 14.7% | $3.72 | $7.40B |
| FY2024ended Dec 31, 2024 | $41.95B | +4.6% | $13.40B | 32.0% | $7.64 | $6.35B |
| FY2023ended Dec 31, 2023 | $40.11B | −8.1% | $5.72B | 14.3% | $3.26 | $5.06B |
| FY2022ended Dec 31, 2022 | $43.65B | +1.3% | $6.93B | 15.9% | $3.91 | $7.80B |
| FY2021ended Dec 31, 2021 | $43.08B | +24.5% | $7.07B | 16.4% | $3.94 | $8.65B |
| FY2020ended Dec 31, 2020 | $34.61B | +8.5% | $4.50B | 13.0% | $2.50 | $5.72B |
| FY2019ended Dec 31, 2019 | $31.90B | +4.3% | $3.69B | 11.6% | $2.06 | $4.50B |
| FY2018ended Dec 31, 2018 | $30.58B | +11.6% | $2.37B | 7.7% | $1.33 | $4.91B |
| FY2017ended Dec 31, 2017 | $27.39B | +31.4% | $477.00M | 1.7% | $0.27 | $4.44B |
| FY2016ended Dec 31, 2016 | $20.85B | — | $1.40B | 6.7% | $0.94 | $2.08B |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q1 FY2026ended Mar 31, 2026 | $11.16B | $1.08B | $0.61 |
| Q4 FY2025ended Dec 31, 2025 | $11.46B | $1.78B | — |
| Q3 FY2025ended Sep 30, 2025 | $11.37B | $1.64B | $0.94 |
| Q2 FY2025ended Jun 30, 2025 | $11.14B | $1.78B | $1.01 |
| Q1 FY2025ended Mar 31, 2025 | $10.36B | $1.33B | $0.76 |
| Q4 FY2024ended Dec 31, 2024 | $10.97B | $9.23B | — |
| Q3 FY2024ended Sep 30, 2024 | $10.64B | $1.65B | $0.94 |
| Q2 FY2024ended Jun 30, 2024 | $10.38B | $1.30B | $0.74 |
Company profile
- Name
- Abbott Laboratories
- Ticker
- ABT
- Exchange
- NYSE
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 100 Abbott Park Road, Abbott Park, IL 60064-3500
- Incorporated in
- IL
- Fiscal year ends
- December
- SEC CIK
- 0000001800
Recent SEC filings
- Aug 20, 2026
- Jul 28, 2026
- Jul 16, 2026
- Apr 29, 2026
- Apr 27, 2026
- Apr 17, 2026
- Apr 16, 2026
- Mar 23, 2026
Frequently asked questions
What is Abbott Laboratories's stock price?
Abbott Laboratories (ABT) closed at $1,064.49 on Oct 9, 2026, down 0.98% from the previous close of $1,075.07.
How much revenue does Abbott Laboratories make?
Abbott Laboratories reported revenue of $44.33B for fiscal 2025, up 5.67% from fiscal 2024.
Does Abbott Laboratories pay a dividend?
Yes. Abbott Laboratories declared $2.44 per share in dividends over the last four quarters, a yield of 0.23%.
Sources and methodology
Fundamentals come from Abbott Laboratories's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures